IL6 and episodic ataxia type 2: Still, dexamethasone treatment and anti-IL-6 strategies might also result in increased susceptibility to superinfections [30,31], including CAPA [32], and could lead to increases in CAPA incidence, emphasizing the need for clinical guidelines.